Tonix Pharmaceuticals Holding (TNXP) Soars with high volume after Positive Phase 3 RELIEF Study Results
Tonix obtains positive results for its TNX-102 SL 5.6 mg Dose in pain reduction over placebo after a testing time of 14 weeks. Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) are rallying today after the company announced high-end top results for TNX-102 SL in its